Retatrutide vs Saxenda: Not Even Close
Retatrutide (24-28% loss, once weekly) is dramatically superior to Saxenda (5-10% loss, daily injections). Saxenda is essentially obsolete.
Quick Comparison
| Feature | Retatrutide | Saxenda (Liraglutide) |
|---|---|---|
| Weight Loss | 24-28.7% | 5-10% |
| Injection Frequency | Once weekly | DAILY |
| Mechanism | Triple agonist (GLP-1, GIP, glucagon) | GLP-1 only |
| FDA Status | Phase 3 trials (2027) | ✅ Approved (2014) |
| Cost | $400-700/mo (estimated) | $1,200-1,500/mo |
Why Saxenda Is Obsolete
❌ Saxenda: Worst Option Available
Saxenda was the FIRST GLP-1 approved for weight loss (2014), but it's now completely outclassed by newer medications:
- • Weakest results: 5-10% weight loss (vs 24-28% for retatrutide, 15-22% for tirzepatide)
- • Daily injections: 365 injections/year vs 52 with weekly options
- • Most expensive: $1,200-1,500/mo (vs $179-499 for tirzepatide)
- • Older technology: First-generation GLP-1, no GIP or glucagon activation
Bottom line: There is virtually NO reason to use Saxenda in 2026. Semaglutide (Wegovy), tirzepatide (Zepbound), or retatrutide (when available) are all dramatically superior.
Better Alternatives to Saxenda (Available NOW)
Tirzepatide
15-22.5%
2-4x better than Saxenda
- ✅ Weekly injections
- ✅ $179-499/mo
- ✅ Available NOW
Semaglutide
10-15%
2x better than Saxenda
- ✅ Weekly injections
- ✅ $349-599/mo
- ✅ Available NOW
Retatrutide
24-28.7%
4-5x better than Saxenda
- ✅ Weekly injections
- ✅ $400-700/mo (est.)
- ⏳ Available 2027
Don't Use Saxenda—It's Obsolete
Switch to tirzepatide (2-4x better results, weekly injections, CHEAPER than Saxenda).
Upgrade to Tirzepatide ($179/mo) →